全新好(000007.SZ):將保留對《中國證券報》及記者於濛濛的訴訟權利
格隆匯4月10日丨全新好(000007.SZ)公佈,公司關注到近日《中國證券報》刊登了記者於濛濛發表的《獲贈日本“黑科技”引爭議全新好背後浮出潮汕資本》的報道。
日本Eleten株式會社將其在日本獲取的正式技術專利授權給公司,同時該項專利於2018年10月10日在中國申請註冊備案登記。在沒有權威科學認定機構認定及合理科學論證的情況下,《中國證券報》記者於濛濛對該專利技術作出“偽科學”的定性報道損害上市公司名譽,對此公司將保留對《中國證券報》及記者於濛濛的訴訟權利,同時公司將統計該事項造成的損失向其進行追訴索賠。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.